Clinical Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Tests for Diagnosing Coronavirus Disease 2019
- PMID: 32818146
- PMCID: PMC7423294
- DOI: 10.1093/ofid/ofaa315
Clinical Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Tests for Diagnosing Coronavirus Disease 2019
Abstract
Utilizing 34 348 severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) nucleic acid amplification test (NAAT) results from 2 health systems, we estimated the clinical sensitivity of a single SARS-CoV-2 NAAT. We found that SARS-CoV-2 NAAT has 82%-97% sensitivity for diagnosing coronavirus disease 2019 among symptomatic patients.
Keywords: COVID-19; SARS-CoV-2.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
References
-
- Food and Drug Administration. Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing under Clinical Laboratory Improvement Amendments (CLIA) prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency. Vol. 85: Washington, DC: Federal; Register: pp 13169–70.
-
- Saah AJ, Hoover DR. “Sensitivity” and “specificity” reconsidered: the meaning of these terms in analytical and diagnostic settings. Ann Intern Med 1997; 126:91–4. - PubMed
-
- Basu A, Zinger T, Inglima K, et al. . Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution. J Clin Microbiol 2020; 58(8):e01136–20. doi: 10.1128/JCM.01136-20 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
